{"id":2794,"date":"2007-05-09T15:50:28","date_gmt":"2007-05-09T13:50:28","guid":{"rendered":"https:\/\/www.rcts.fr\/uncategorized\/comparison-of-efficacy-and-safety-of-cyclosporine-csa-discontinuation-with-introduction-of-sirolimus-srl-at-week-12-to-standard-strategy-in-renal-transplant-recipients-receiving-mycophenolate-mofe"},"modified":"2020-04-07T16:16:13","modified_gmt":"2020-04-07T14:16:13","slug":"comparison-of-efficacy-and-safety-of-cyclosporine-csa-discontinuation-with-introduction-of-sirolimus-srl-at-week-12-to-standard-strategy-in-renal-transplant-recipients-receiving-mycophenolate-mofe","status":"publish","type":"post","link":"https:\/\/www.rcts.fr\/en\/comparison-of-efficacy-and-safety-of-cyclosporine-csa-discontinuation-with-introduction-of-sirolimus-srl-at-week-12-to-standard-strategy-in-renal-transplant-recipients-receiving-mycophenolate-mofe\/","title":{"rendered":"Comparison of Efficacy and Safety of Cyclosporine (CsA) Discontinuation with Introduction of Sirolimus (SRL) at Week 12 to Standard Strategy in Renal Transplant Recipients Receiving Mycophenolate Mofetil (MMF)"},"content":{"rendered":"<table border=\"0\" width=\"538\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td class=\"xl70\" width=\"292\" height=\"102\">American Transplant Congress 2007 meeting at the Moscone West Convention Center, San Francisco, California, May 5\u22129, 2007<\/td>\n<td class=\"xl69\" width=\"246\">Lebranchu Y, Etienne I, Touchard G, Thervet E, Westeel PF, Toupance O, Hurault de Ligny B, Moulin B, Frouget T, Le Meur Y, Glotz D, Mignon F, Deteix P, Subra JF, Bayle F, Noel C, Hayem C, Girardot-Seguin S and Buchler M.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>American Transplant Congress 2007 meeting at the Moscone West Convention Center, San Francisco, California, May 5\u22129, 2007 Lebranchu Y, Etienne I, Touchard G, Thervet E, Westeel PF, Toupance O, Hurault de Ligny B, Moulin B, Frouget T, Le Meur Y, Glotz D, Mignon F, Deteix P, Subra JF, Bayle F, Noel C, Hayem C, Girardot-Seguin [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false},"categories":[67],"class_list":["post-2794","post","type-post","status-publish","format-standard","hentry","category-transplantation-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Comparison of Efficacy and Safety of Cyclosporine (CsA) Discontinuation with Introduction of Sirolimus (SRL) at Week 12 to Standard Strategy in Renal Transplant Recipients Receiving Mycophenolate Mofetil (MMF) - RCTs<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/www.rcts.fr\/en\/comparison-of-efficacy-and-safety-of-cyclosporine-csa-discontinuation-with-introduction-of-sirolimus-srl-at-week-12-to-standard-strategy-in-renal-transplant-recipients-receiving-mycophenolate-mofe\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Comparison of Efficacy and Safety of Cyclosporine (CsA) Discontinuation with Introduction of Sirolimus (SRL) at Week 12 to Standard Strategy in Renal Transplant Recipients Receiving Mycophenolate Mofetil (MMF) - RCTs\" \/>\n<meta property=\"og:description\" content=\"American Transplant Congress 2007 meeting at the Moscone West Convention Center, San Francisco, California, May 5\u22129, 2007 Lebranchu Y, Etienne I, Touchard G, Thervet E, Westeel PF, Toupance O, Hurault de Ligny B, Moulin B, Frouget T, Le Meur Y, Glotz D, Mignon F, Deteix P, Subra JF, Bayle F, Noel C, Hayem C, Girardot-Seguin [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"http:\/\/www.rcts.fr\/en\/comparison-of-efficacy-and-safety-of-cyclosporine-csa-discontinuation-with-introduction-of-sirolimus-srl-at-week-12-to-standard-strategy-in-renal-transplant-recipients-receiving-mycophenolate-mofe\/\" \/>\n<meta property=\"og:site_name\" content=\"RCTs\" \/>\n<meta property=\"article:published_time\" content=\"2007-05-09T13:50:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-04-07T14:16:13+00:00\" \/>\n<meta name=\"author\" content=\"Didier Not\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Didier Not\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/comparison-of-efficacy-and-safety-of-cyclosporine-csa-discontinuation-with-introduction-of-sirolimus-srl-at-week-12-to-standard-strategy-in-renal-transplant-recipients-receiving-mycophenolate-mofe\\\/#article\",\"isPartOf\":{\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/comparison-of-efficacy-and-safety-of-cyclosporine-csa-discontinuation-with-introduction-of-sirolimus-srl-at-week-12-to-standard-strategy-in-renal-transplant-recipients-receiving-mycophenolate-mofe\\\/\"},\"author\":{\"name\":\"Didier Not\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/person\\\/19ff6b0ca72b83f30ac0a23e6ce05dc5\"},\"headline\":\"Comparison of Efficacy and Safety of Cyclosporine (CsA) Discontinuation with Introduction of Sirolimus (SRL) at Week 12 to Standard Strategy in Renal Transplant Recipients Receiving Mycophenolate Mofetil (MMF)\",\"datePublished\":\"2007-05-09T13:50:28+00:00\",\"dateModified\":\"2020-04-07T14:16:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/comparison-of-efficacy-and-safety-of-cyclosporine-csa-discontinuation-with-introduction-of-sirolimus-srl-at-week-12-to-standard-strategy-in-renal-transplant-recipients-receiving-mycophenolate-mofe\\\/\"},\"wordCount\":83,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#organization\"},\"articleSection\":[\"Transplantation\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/comparison-of-efficacy-and-safety-of-cyclosporine-csa-discontinuation-with-introduction-of-sirolimus-srl-at-week-12-to-standard-strategy-in-renal-transplant-recipients-receiving-mycophenolate-mofe\\\/\",\"url\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/comparison-of-efficacy-and-safety-of-cyclosporine-csa-discontinuation-with-introduction-of-sirolimus-srl-at-week-12-to-standard-strategy-in-renal-transplant-recipients-receiving-mycophenolate-mofe\\\/\",\"name\":\"Comparison of Efficacy and Safety of Cyclosporine (CsA) Discontinuation with Introduction of Sirolimus (SRL) at Week 12 to Standard Strategy in Renal Transplant Recipients Receiving Mycophenolate Mofetil (MMF) - RCTs\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#website\"},\"datePublished\":\"2007-05-09T13:50:28+00:00\",\"dateModified\":\"2020-04-07T14:16:13+00:00\",\"breadcrumb\":{\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/comparison-of-efficacy-and-safety-of-cyclosporine-csa-discontinuation-with-introduction-of-sirolimus-srl-at-week-12-to-standard-strategy-in-renal-transplant-recipients-receiving-mycophenolate-mofe\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\\\/\\\/www.rcts.fr\\\/en\\\/comparison-of-efficacy-and-safety-of-cyclosporine-csa-discontinuation-with-introduction-of-sirolimus-srl-at-week-12-to-standard-strategy-in-renal-transplant-recipients-receiving-mycophenolate-mofe\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\\\/\\\/www.rcts.fr\\\/en\\\/comparison-of-efficacy-and-safety-of-cyclosporine-csa-discontinuation-with-introduction-of-sirolimus-srl-at-week-12-to-standard-strategy-in-renal-transplant-recipients-receiving-mycophenolate-mofe\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Comparison of Efficacy and Safety of Cyclosporine (CsA) Discontinuation with Introduction of Sirolimus (SRL) at Week 12 to Standard Strategy in Renal Transplant Recipients Receiving Mycophenolate Mofetil (MMF)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#website\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/\",\"name\":\"RCTs\",\"description\":\"Description\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.rcts.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#organization\",\"name\":\"RCTs\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/wp-content\\\/uploads\\\/logo-blue.svg\",\"contentUrl\":\"https:\\\/\\\/www.rcts.fr\\\/wp-content\\\/uploads\\\/logo-blue.svg\",\"width\":163,\"height\":47,\"caption\":\"RCTs\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/person\\\/19ff6b0ca72b83f30ac0a23e6ce05dc5\",\"name\":\"Didier Not\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g\",\"caption\":\"Didier Not\"},\"url\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/author\\\/dnorcts-fr\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Comparison of Efficacy and Safety of Cyclosporine (CsA) Discontinuation with Introduction of Sirolimus (SRL) at Week 12 to Standard Strategy in Renal Transplant Recipients Receiving Mycophenolate Mofetil (MMF) - RCTs","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/www.rcts.fr\/en\/comparison-of-efficacy-and-safety-of-cyclosporine-csa-discontinuation-with-introduction-of-sirolimus-srl-at-week-12-to-standard-strategy-in-renal-transplant-recipients-receiving-mycophenolate-mofe\/","og_locale":"en_US","og_type":"article","og_title":"Comparison of Efficacy and Safety of Cyclosporine (CsA) Discontinuation with Introduction of Sirolimus (SRL) at Week 12 to Standard Strategy in Renal Transplant Recipients Receiving Mycophenolate Mofetil (MMF) - RCTs","og_description":"American Transplant Congress 2007 meeting at the Moscone West Convention Center, San Francisco, California, May 5\u22129, 2007 Lebranchu Y, Etienne I, Touchard G, Thervet E, Westeel PF, Toupance O, Hurault de Ligny B, Moulin B, Frouget T, Le Meur Y, Glotz D, Mignon F, Deteix P, Subra JF, Bayle F, Noel C, Hayem C, Girardot-Seguin [&hellip;]","og_url":"http:\/\/www.rcts.fr\/en\/comparison-of-efficacy-and-safety-of-cyclosporine-csa-discontinuation-with-introduction-of-sirolimus-srl-at-week-12-to-standard-strategy-in-renal-transplant-recipients-receiving-mycophenolate-mofe\/","og_site_name":"RCTs","article_published_time":"2007-05-09T13:50:28+00:00","article_modified_time":"2020-04-07T14:16:13+00:00","author":"Didier Not","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Didier Not"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"http:\/\/www.rcts.fr\/en\/comparison-of-efficacy-and-safety-of-cyclosporine-csa-discontinuation-with-introduction-of-sirolimus-srl-at-week-12-to-standard-strategy-in-renal-transplant-recipients-receiving-mycophenolate-mofe\/#article","isPartOf":{"@id":"http:\/\/www.rcts.fr\/en\/comparison-of-efficacy-and-safety-of-cyclosporine-csa-discontinuation-with-introduction-of-sirolimus-srl-at-week-12-to-standard-strategy-in-renal-transplant-recipients-receiving-mycophenolate-mofe\/"},"author":{"name":"Didier Not","@id":"https:\/\/www.rcts.fr\/#\/schema\/person\/19ff6b0ca72b83f30ac0a23e6ce05dc5"},"headline":"Comparison of Efficacy and Safety of Cyclosporine (CsA) Discontinuation with Introduction of Sirolimus (SRL) at Week 12 to Standard Strategy in Renal Transplant Recipients Receiving Mycophenolate Mofetil (MMF)","datePublished":"2007-05-09T13:50:28+00:00","dateModified":"2020-04-07T14:16:13+00:00","mainEntityOfPage":{"@id":"http:\/\/www.rcts.fr\/en\/comparison-of-efficacy-and-safety-of-cyclosporine-csa-discontinuation-with-introduction-of-sirolimus-srl-at-week-12-to-standard-strategy-in-renal-transplant-recipients-receiving-mycophenolate-mofe\/"},"wordCount":83,"commentCount":0,"publisher":{"@id":"https:\/\/www.rcts.fr\/#organization"},"articleSection":["Transplantation"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"http:\/\/www.rcts.fr\/en\/comparison-of-efficacy-and-safety-of-cyclosporine-csa-discontinuation-with-introduction-of-sirolimus-srl-at-week-12-to-standard-strategy-in-renal-transplant-recipients-receiving-mycophenolate-mofe\/","url":"http:\/\/www.rcts.fr\/en\/comparison-of-efficacy-and-safety-of-cyclosporine-csa-discontinuation-with-introduction-of-sirolimus-srl-at-week-12-to-standard-strategy-in-renal-transplant-recipients-receiving-mycophenolate-mofe\/","name":"Comparison of Efficacy and Safety of Cyclosporine (CsA) Discontinuation with Introduction of Sirolimus (SRL) at Week 12 to Standard Strategy in Renal Transplant Recipients Receiving Mycophenolate Mofetil (MMF) - RCTs","isPartOf":{"@id":"https:\/\/www.rcts.fr\/#website"},"datePublished":"2007-05-09T13:50:28+00:00","dateModified":"2020-04-07T14:16:13+00:00","breadcrumb":{"@id":"http:\/\/www.rcts.fr\/en\/comparison-of-efficacy-and-safety-of-cyclosporine-csa-discontinuation-with-introduction-of-sirolimus-srl-at-week-12-to-standard-strategy-in-renal-transplant-recipients-receiving-mycophenolate-mofe\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/www.rcts.fr\/en\/comparison-of-efficacy-and-safety-of-cyclosporine-csa-discontinuation-with-introduction-of-sirolimus-srl-at-week-12-to-standard-strategy-in-renal-transplant-recipients-receiving-mycophenolate-mofe\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/www.rcts.fr\/en\/comparison-of-efficacy-and-safety-of-cyclosporine-csa-discontinuation-with-introduction-of-sirolimus-srl-at-week-12-to-standard-strategy-in-renal-transplant-recipients-receiving-mycophenolate-mofe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.rcts.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Comparison of Efficacy and Safety of Cyclosporine (CsA) Discontinuation with Introduction of Sirolimus (SRL) at Week 12 to Standard Strategy in Renal Transplant Recipients Receiving Mycophenolate Mofetil (MMF)"}]},{"@type":"WebSite","@id":"https:\/\/www.rcts.fr\/#website","url":"https:\/\/www.rcts.fr\/","name":"RCTs","description":"Description","publisher":{"@id":"https:\/\/www.rcts.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rcts.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.rcts.fr\/#organization","name":"RCTs","url":"https:\/\/www.rcts.fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rcts.fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.rcts.fr\/wp-content\/uploads\/logo-blue.svg","contentUrl":"https:\/\/www.rcts.fr\/wp-content\/uploads\/logo-blue.svg","width":163,"height":47,"caption":"RCTs"},"image":{"@id":"https:\/\/www.rcts.fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.rcts.fr\/#\/schema\/person\/19ff6b0ca72b83f30ac0a23e6ce05dc5","name":"Didier Not","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/384084503863c2fae1497cd4aff02d7d7ec7ec0d357eb358655b55a5dd586850?s=96&d=mm&r=g","caption":"Didier Not"},"url":"https:\/\/www.rcts.fr\/en\/author\/dnorcts-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts\/2794","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/comments?post=2794"}],"version-history":[{"count":1,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts\/2794\/revisions"}],"predecessor-version":[{"id":2796,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts\/2794\/revisions\/2796"}],"wp:attachment":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/media?parent=2794"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/categories?post=2794"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}